JP2018535681A - Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法 - Google Patents

Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法 Download PDF

Info

Publication number
JP2018535681A
JP2018535681A JP2018526797A JP2018526797A JP2018535681A JP 2018535681 A JP2018535681 A JP 2018535681A JP 2018526797 A JP2018526797 A JP 2018526797A JP 2018526797 A JP2018526797 A JP 2018526797A JP 2018535681 A JP2018535681 A JP 2018535681A
Authority
JP
Japan
Prior art keywords
colitis
antisense oligonucleotide
disease
fibrosis
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018526797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535681A5 (https=
Inventor
マリー マクナルティ，
マリー マクナルティ，
フランチェスカ ヴィティ，
フランチェスカ ヴィティ，
サルヴァトーレ ベッリンヴィア，
サルヴァトーレ ベッリンヴィア，
Original Assignee
ノグラ ファーマ リミテッド
ノグラ ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノグラ ファーマ リミテッド, ノグラ ファーマ リミテッド filed Critical ノグラ ファーマ リミテッド
Publication of JP2018535681A publication Critical patent/JP2018535681A/ja
Publication of JP2018535681A5 publication Critical patent/JP2018535681A5/ja
Priority to JP2021078549A priority Critical patent/JP2021106625A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018526797A 2015-11-25 2016-11-25 Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法 Pending JP2018535681A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021078549A JP2021106625A (ja) 2015-11-25 2021-05-06 Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562260076P 2015-11-25 2015-11-25
US62/260,076 2015-11-25
PCT/EP2016/078833 WO2017089555A1 (en) 2015-11-25 2016-11-25 Il-34 antisense oligonucleotides and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021078549A Division JP2021106625A (ja) 2015-11-25 2021-05-06 Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2018535681A true JP2018535681A (ja) 2018-12-06
JP2018535681A5 JP2018535681A5 (https=) 2020-01-09

Family

ID=57471829

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018526797A Pending JP2018535681A (ja) 2015-11-25 2016-11-25 Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法
JP2021078549A Pending JP2021106625A (ja) 2015-11-25 2021-05-06 Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021078549A Pending JP2021106625A (ja) 2015-11-25 2021-05-06 Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法

Country Status (13)

Country Link
US (1) US20180338992A1 (https=)
EP (1) EP3380615B1 (https=)
JP (2) JP2018535681A (https=)
KR (1) KR20180084956A (https=)
CN (1) CN108473989A (https=)
AU (1) AU2016360956A1 (https=)
BR (1) BR112018010736A2 (https=)
CA (1) CA3005932A1 (https=)
ES (1) ES2861516T3 (https=)
MA (1) MA44309A (https=)
MX (1) MX2018006445A (https=)
PT (1) PT3380615T (https=)
WO (1) WO2017089555A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023503804A (ja) * 2019-11-15 2023-02-01 ノグラ ファーマ リミテッド Ｉｌ－３４アンチセンス薬剤、およびこれを使用する方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505598A (ja) * 2016-02-23 2019-02-28 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法
AU2022276078A1 (en) 2021-05-17 2024-01-04 Nogra Pharma Limited Il-34 antisense agents and methods of using same
WO2022243299A1 (en) * 2021-05-17 2022-11-24 Nogra Pharma Limited Il-34 antisense agents and methods of using same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530512A (ja) * 2009-06-23 2012-12-06 ユニヴァーシティ コート オブ ザ ユニバーシティ オブ エディンバラ 鳥類コロニー刺激因子１受容体結合タンパク質
JP2013529183A (ja) * 2010-04-01 2013-07-18 イムクローン・リミテッド・ライアビリティ・カンパニー Ｃｓｆ−１ｒに対する抗体
WO2014036357A1 (en) * 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
JP2014520873A (ja) * 2011-07-18 2014-08-25 ザ ユニバーシティ オブ メルボルン ｃ−Ｆｍｓアンタゴニストの使用
WO2015028454A2 (en) * 2013-08-30 2015-03-05 Ucb Biopharma Sprl Method for the treatment of fibrotic disease
KR20150104275A (ko) * 2014-03-05 2015-09-15 울산대학교 산학협력단 비만 관련 질환의 진단과 치료를 위한 il-34의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2009090639A2 (en) * 2008-01-15 2009-07-23 Quark Pharmaceuticals, Inc. Sirna compounds and methods of use thereof
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
WO2011097407A1 (en) * 2010-02-04 2011-08-11 Ico Therapeutics Inc. Dosing regimens for treating and preventing ocular disorders using c-raf antisense
ES3047792T3 (en) * 2014-07-14 2025-12-04 Univ California Crispr/cas transcriptional modulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530512A (ja) * 2009-06-23 2012-12-06 ユニヴァーシティ コート オブ ザ ユニバーシティ オブ エディンバラ 鳥類コロニー刺激因子１受容体結合タンパク質
JP2013529183A (ja) * 2010-04-01 2013-07-18 イムクローン・リミテッド・ライアビリティ・カンパニー Ｃｓｆ−１ｒに対する抗体
JP2014520873A (ja) * 2011-07-18 2014-08-25 ザ ユニバーシティ オブ メルボルン ｃ−Ｆｍｓアンタゴニストの使用
WO2014036357A1 (en) * 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2015028454A2 (en) * 2013-08-30 2015-03-05 Ucb Biopharma Sprl Method for the treatment of fibrotic disease
KR20150104275A (ko) * 2014-03-05 2015-09-15 울산대학교 산학협력단 비만 관련 질환의 진단과 치료를 위한 il-34의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"IL-34 Antibody Ameliorates Experimental Colitis by Alternating IL-12p40 Expression in Macrophages (A", GASTROENTEROLOGY, vol. Vol.148, No.4, Suppl.1, JPN6020042008, April 2015 (2015-04-01), pages 8, ISSN: 0004764124 *
PNAS, vol. 109, no. 25, JPN6020042005, 2012, pages 10006 - 10011, ISSN: 0004379138 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023503804A (ja) * 2019-11-15 2023-02-01 ノグラ ファーマ リミテッド Ｉｌ－３４アンチセンス薬剤、およびこれを使用する方法

Also Published As

Publication number Publication date
ES2861516T3 (es) 2021-10-06
MA44309A (fr) 2018-10-03
EP3380615B1 (en) 2021-01-06
CA3005932A1 (en) 2017-06-01
PT3380615T (pt) 2021-04-01
BR112018010736A2 (pt) 2018-11-27
JP2021106625A (ja) 2021-07-29
AU2016360956A1 (en) 2018-06-07
US20180338992A1 (en) 2018-11-29
WO2017089555A1 (en) 2017-06-01
KR20180084956A (ko) 2018-07-25
CN108473989A (zh) 2018-08-31
EP3380615A1 (en) 2018-10-03
MX2018006445A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
JP6348484B2 (ja) 糖尿病を処置する方法および／または移植後の膵島の生存を促進する方法
JP2021106625A (ja) Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法
US10006029B2 (en) Methods of treating colorectal cancer
AU2014229985B2 (en) Methods of treating colorectal cancer
US20180113139A1 (en) Methods and compositions for diagnosing and treating inflammatory bowel disorders
US20230002770A1 (en) Il-34 antisense agents and methods of using same
KR20240009973A (ko) Il-34 안티센스 작용제 및 이의 사용 방법
Theiss The roles of growth hormone and tumor necrosis factor α in inflammation-induced intestinal fibrosis
HK1219489B (en) Methods of treating colorectal cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220506